Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 1/20 | 0.69 |
| ▸ | AKR1C3 | P42330 | 13/20 | 0.67 |
| ▸ | AKR1C2 | P52895 | 13/20 | 0.67 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.67 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.67 |
| ▸ | CDC42 | P60953 | 1/20 | 0.67 |
| ▸ | RAC1 | P63000 | 1/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.67 |
| ▸ | TSHR | P16473 | 1/20 | 0.67 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.67 |
| ▸ | UGT2B7 | P16662 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12431128 | 1.00 | AKR1B1 (0.69) | AKR1B1AKR1C3AKR1C2PTGS2PTGS1 | |
| SCHEMBL30717241 | 1.00 | AKR1B1 (0.69) | AKR1B1AKR1C3AKR1C2PTGS2PTGS1 | |
| SCHEMBL10025981 | 1.00 | AKR1B1 (0.69) | AKR1B1AKR1C3AKR1C2PTGS2PTGS1 | |
| SCHEMBL4679446 | 1.00 | AKR1B1 (0.69) | AKR1B1AKR1C3AKR1C2PTGS2PTGS1 | |
| Hydrochloric Acid SCHEMBL27401798 | 0.98 | AKR1B1 (0.67) | AKR1B1AKR1C3AKR1C2PTGS2PTGS1 | |
| SCHEMBL503391 | 0.93 | AKR1B1 (0.61) | AKR1B1AKR1C3AKR1C2PTGS2PTGS1 | |
| SCHEMBL11470486 | 0.90 | AKR1C3 (0.69) | AKR1B1AKR1C3AKR1C2PTGS2PTGS1 | |
| Naproxen SCHEMBL23753934 | 0.89 | AKR1C3 (0.88) | AKR1B1AKR1C3AKR1C2PTGS2PTGS1 | |
| Ammonia Solution, Strong SCHEMBL11721423 | 0.89 | AKR1C3 (0.67) | AKR1B1AKR1C3AKR1C2PTGS2PTGS1 | |
| SCHEMBL15695558 | 0.89 | UGT2B7 (0.60) | AKR1B1AKR1C3AKR1C2PTGS2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 125 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113862058-B | Lubricating oil composition and preparation method thereof | 中国石油化工股份有限公司（CN） | 2023-01-13 | — | — | CN | claimed |
| CN-114502152-A | Pharmaceutical composition for topical use in the form of a dispersed phase based on at least one short-chain diol and comprising at least one anti-inflammatory substance in a continuous fatty phase | 化工产品开发公司SEPPIC | 2022-05-13 | — | — | CN | claimed |
| CN-113861031-A | Ester compound, preparation method and application thereof, and lubricating oil composition | 中国石油化工股份有限公司 | 2021-12-31 | — | — | CN | claimed |
| CN-113862058-A | Lubricating oil composition and preparation method thereof | 中国石油化工股份有限公司 | 2021-12-31 | — | — | CN | claimed |
| CN-113861032-A | Ester compound, preparation method and application thereof, and lubricating oil composition | 中国石油化工股份有限公司 | 2021-12-31 | — | — | CN | claimed |
| CN-112739326-A | Pharmaceutical composition for topical use comprising at least one anti-inflammatory substance | 化工产品开发公司SEPPIC | 2021-04-30 | — | — | CN | claimed |
| CN-107935874-A | A kind of synthetic method of (R) 3 amino 3 (2 naphthyl) propionic acid | 康化（上海）新药研发有限公司 | 2018-04-20 | — | — | CN | claimed |
| EP-0220805-B1 | MULTIPHASE TABLET AND PROCESS FOR THE PREPARATION THEREOF | Euroceltique S.A. (LU) | 1989-09-20 | — | — | EP | claimed |
| EP-0220805-A2 | Multiphase tablet and process for the preparation thereof | Euroceltique S.A. (LU) | 1987-05-06 | — | — | EP | claimed |
| US-20240409598-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR | JANSSEN BIOTECH INC (US) | 2024-12-12 | — | — | US | disclosed |
| EP-4249470-B1 | METHOD FOR PREPARING ALPHA-AMINO ACIDS | PHILIPPS UNIV MARBURG (DE) | 2024-11-13 | — | — | EP | disclosed |
| US-20240352073-A1 | BICYCLIC PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR | JANSSEN BIOTECH INC (US) | 2024-10-24 | — | — | US | disclosed |
| US-20240200049-A1 | COMPOSITIONS AND METHODS OF USE THEREOF FOR MAKING POLYPEPTIDES WITH MANY INSTANCES OF NONSTANDARD AMINO ACIDS | YALE UNIVERSITY | 2024-06-20 | — | — | US | disclosed |
| EP-4367237-A2 | BIS-RNAI COMPOUNDS FOR CNS DELIVERY | Alnylam Pharmaceuticals, Inc. (US) | 2024-05-15 | — | — | EP | disclosed |
| US-4009197-A | 2-(6-Substituted-2'-naphthyl) acetic acid derivatives and the salts and esters thereof | SYNTEX CORPORATION (PM) | 1977-02-22 | — | — | US | disclosed |
| US-4001301-A | ANTIINFLAMMATORY AGENTS, ANALGESICS, ANTIPYRETICS, ANTI-PRURITIC | SYNTEX CORPORATION (PM) | 1977-01-04 | — | — | US | disclosed |
| US-3998966-A | Anti-inflammatory, analgesic, anti-pyretic and anti-pruritic 6-substituted 2-naphthyl acetic acid derivative-containing compositions and methods of use thereof | SYNTEX CORPORATION (PM) | 1976-12-21 | — | — | US | disclosed |
| US-3980699-A | ANTIINFLAMMATORY, ANALGESICS, ANTIPYRETIC, ANTIPRURITIC | SYNTEX CORPORATION (PM) | 1976-09-14 | — | — | US | disclosed |
| US-3978124-A | ANALGESIC, ANTIPYRETIC | SYNTEX CORPORATION (PM) | 1976-08-31 | — | — | US | disclosed |
| US-3978116-A | ANALGESIC, ANTIPYRETIC | SYNTEX CORPORATION (PM) | 1976-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240352073-A1 | BICYCLIC PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR | IL23R, IL1RN, IL17A | AKR1B1 2109/4885AKR1C3 562/4885AKR1C2 1141/4885 |
| US-20240409598-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR | IL23R, IL1RN, IL36G | AKR1B1 1695/4885AKR1C3 587/4885AKR1C2 1487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.